Lilly will invest more than $700M to boost global insulin production

11/14/2013 | Genetic Engineering & Biotechnology News

Eli Lilly and Co. said it plans to expand its global insulin production capacity in Indiana, Puerto Rico, China and France in response to growing demand for the diabetes treatment. The firm, which has 14 candidates for the treatment of diabetes and related complications in its pipeline, will invest more than $700 million in the expansion project.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ